Report cover image

BioCardia Inc (BCDA) - Product Pipeline Analysis, 2025 Update

Publisher GlobalData
Published Sep 22, 2025
Length 38 Pages
SKU # GBDT20417059

Description

Summary

BioCardia Inc (BioCardia) is a regenerative medicine company that develops cellular and cell-derived therapeutics aimed at treating unmet cardiovascular and pulmonary diseases. The company's pipeline products include CardiAMP, CardiALLO, and PulmALLO. Its products are designed for patients suffering from conditions such as ischemic heart failure and acute respiratory distress syndrome. BioCardia's therapies are utilized in the healthcare industry, specifically targeting medical professionals and institutions involved in cardiovascular and pulmonary care. The company sells its products through a network of distributors across the US. BioCardia is headquartered in San Carlos, California, the US.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:
  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company BioCardia Inc
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

38 Pages
BioCardia Inc Company Overview
BioCardia Inc Company Snapshot
BioCardia Inc Pipeline Products and Ongoing Clinical Trials Overview
BioCardia Inc – Pipeline Analysis Overview
BioCardia Inc - Key Facts
BioCardia Inc - Major Products and Services
BioCardia Inc Pipeline Products by Development Stage
BioCardia Inc Ongoing Clinical Trials by Trial Status
BioCardia Inc Pipeline Products Overview
CardiALLO - Heart Failure
CardiALLO - Heart Failure Product Overview
CardiALLO - Heart Failure Clinical Trial
CardiAMP - Chronic Myocardial Ischemia
CardiAMP - Chronic Myocardial Ischemia Product Overview
CardiAMP - Chronic Myocardial Ischemia Clinical Trial
CardiAMP - Heart Failure
CardiAMP - Heart Failure Product Overview
CardiAMP - Heart Failure Clinical Trial
CardiAMP - Post Acute Infarction
CardiAMP - Post Acute Infarction Product Overview
Fusion Imaging System
Fusion Imaging System Product Overview
Helix Transendocardial Delivery System
Helix Transendocardial Delivery System Product Overview
Helix Transendocardial Delivery System Clinical Trial
BioCardia Inc - Key Competitors
BioCardia Inc - Key Employees
BioCardia Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
BioCardia Inc, Recent Developments
Sep 18, 2025: Biocardia Reports Positive Results from CardiAMP Chronic Myocardial Ischemia Trial
Sep 04, 2025: Biocardia CEO Peter Altman To Present at the H. C. Wainwright 27th Annual Global Investment Conference in New York City September 8-10, 2025
Aug 04, 2025: BioCardia Provides Update on Timing of Regulatory Activities Seeking FDA Approval and Japan PMDA Approval for CardiAMP Cell Therapy for Heart Failure and Helix Transendocardial Delivery Catheter
Jul 24, 2025: BioCardia Submits Request for Clinical Data Review Meeting with Japan PMDA To Discuss Approval Pathway for CardiAMP Cell Therapy in Ischemic Heart Failure
Jul 16, 2025: Henry Ford Health Initiates Patient Enrollment for BioCardia’s CardiAMP HF II Pivotal Study for Ischemic Heart Failure of Reduced Ejection Fraction
Jun 25, 2025: Biocardia Announces New United States Patent for Helix Biotherapeutic Delivery System
May 06, 2025: BioCardia Initiates Patient Enrollment at University of Wisconsin at Madison for Ongoing CardiAMP HF II Pivotal Study
Apr 15, 2025: Biocardia Announces Positive DSMB Review of Cardiallo Allogeneic Cell Therapy for Heart Failure Phase 1/2 Clinical Trial
Mar 31, 2025: Biocardia Phase 3 CardiAMP-HF Trial of Novel Cardiac Cell Therapy for Ischemic Heart Failure Shows Increased Survival, Decreased Cardiac Events, and Improved Quality of Life at Two Years
Mar 10, 2025: BioCardia Announces Japanese Patent for Helix Biotherapeutic Delivery System
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer
List of Tables
BioCardia Inc Pipeline Products and Ongoing Clinical Trials Overview
BioCardia Inc Pipeline Products by Equipment Type
BioCardia Inc Pipeline Products by Indication
BioCardia Inc Ongoing Clinical Trials by Trial Status
BioCardia Inc, Key Facts
BioCardia Inc, Major Products and Services
BioCardia Inc Number of Pipeline Products by Development Stage
BioCardia Inc Pipeline Products Summary by Development Stage
BioCardia Inc Ongoing Clinical Trials by Trial Status
BioCardia Inc Ongoing Clinical Trials Summary
CardiALLO - Heart Failure - Product Status
CardiALLO - Heart Failure - Product Description
CardiALLO - Heart Failure - Phase I/II Clinical Trial of Human Allogenic Culture-expanded Bone Marrow-derived Mesenchymal Stem Cells (hMSCs) in Patients With Ischemic Heart Failure With Reduced Ejection Fraction (HFrEF)
CardiAMP - Chronic Myocardial Ischemia - Product Status
CardiAMP - Chronic Myocardial Ischemia - Product Description
CardiAMP - Chronic Myocardial Ischemia - Randomized Controlled Pivotal Trial of Autologous Bone Marrow Cells Using the CardiAMP Cell Therapy System in Patients with Refractory Angina Pectoris and Chronic Myocardial Ischemia: CardiAMP CMI Trial
CardiAMP - Heart Failure - Product Status
CardiAMP - Heart Failure - Product Description
CardiAMP - Heart Failure - Randomized Controlled Pivotal Trial of Autologous Bone Marrow Mononuclear Cells Using the CardiAMP Cell Therapy System in Patients with Ischemic Heart Failure (CardiAMP Heart Failure Trial)
CardiAMP - Heart Failure - Randomized Controlled Pivotal Trial of Autologous Bone Marrow Mononuclear Cells Using the CardiAMP Cell Therapy System in Patients with Ischemic Heart Failure II Trial
CardiAMP - Post Acute Infarction - Product Status
CardiAMP - Post Acute Infarction - Product Description
Fusion Imaging System - Product Status
Fusion Imaging System - Product Description
Helix Transendocardial Delivery System - Product Status
Helix Transendocardial Delivery System - Product Description
Helix Transendocardial Delivery System - A Multicentric Controlled Phase I / IIb Study Evaluating the Safety and the Efficacy of in Vitro Expanded Peripheral Blood CD34+ Stem Cells Output by the StemXpand Automated Process, and Injected in Patients with an Acute Myocardial Infarction and a Left Ventricle Ejection Fraction (LVEF) Remaining Below or Equal to 45% after PTCA and Stent(s) Implantation Versus Standard of Care
Helix Transendocardial Delivery System - Phase I Trial of Endocavitary Injection of Bone Marrow Derived CD133+ Cells in Ischemic Refractory Cardiomyopathy (RECARDIO Trial)
Helix Transendocardial Delivery System - Randomized Controlled Pivotal Trial of Autologous Bone Marrow Mononuclear Cells Using the CardiAMP Cell Therapy System in Patients with Ischemic Heart Failure (CardiAMP Heart Failure Trial)
BioCardia Inc, Key Employees
BioCardia Inc, Subsidiaries
Glossary
List of Figures
BioCardia Inc Pipeline Products by Equipment Type
BioCardia Inc Pipeline Products by Development Stage
BioCardia Inc Ongoing Clinical Trials by Trial Status

Search Inside Report

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us